Related Experiment Video

Updated: Sep 21, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

230

Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure

Xiao Zong1,2, Qin Fan1, Qian Yang1,2

  • 1Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

ESC Heart Failure
|May 28, 2022
PubMed

Insights

Serum phenylacetylglutamine (PAGln) is elevated in chronic heart failure (HF) patients and indicates a higher risk of cardiovascular death and renal dysfunction. PAGln serves as a valuable biomarker for HF.

Area of Science:

  • Biochemistry
  • Cardiology
  • Nephrology

Background:

  • Heart failure (HF) is a complex clinical syndrome with significant morbidity and mortality.
  • Identifying novel biomarkers for HF risk stratification and management is crucial.

Purpose of the Study:

  • To investigate the association between serum phenylacetylglutamine (PAGln) and chronic heart failure (HF).
  • To evaluate PAGln as a potential indicator of HF risk, renal dysfunction, and cardiovascular mortality.

Main Methods:

  • Serum PAGln levels were measured in 956 subjects using liquid chromatography-tandem mass spectrometry.
  • Correlation and regression analyses assessed the association between PAGln, HF, and renal indicators.
  • Kaplan-Meier curves and Cox proportional hazards analysis evaluated the prognostic value of PAGln in HF patients.

Main Results:

  • Serum PAGln levels were significantly higher in chronic HF patients compared to controls (3.322 ± 8.220 μM vs. 1.249 ± 1.168 μM, P < 0.001).
  • Elevated PAGln was independently associated with HF risk (OR, 1.507; P < 0.001) and renal dysfunction (OR, 1.853; P < 0.001).
  • High PAGln levels predicted increased risk of cardiovascular death in HF patients (HR, 2.049; P = 0.038).

Conclusions:

  • Elevated serum PAGln is an independent risk factor for chronic heart failure.
  • High PAGln levels are associated with increased risk of cardiovascular death and may indicate renal dysfunction in HF patients.
  • PAGln shows potential as a valuable biomarker for HF assessment and prognosis.
Abstract

Keywords:
Gut microbiotaHeart failurePhenylacetylglutaminePrognosisRenal dysfunction

More Related Videos

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics08:01

LERLIC-MS/MS for In-depth Characterization and Quantification of Glutamine and Asparagine Deamidation in Shotgun Proteomics

Published on: April 9, 2017

8.2K
Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer08:37

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Published on: November 15, 2024

405

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
230
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
67
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
149
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
62
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
47